Resveratrol, from experimental data to nutritional evidence: The emergence of a new food ingredient

Annals of the New York Academy of Sciences

Volumn 1290, Issue 1, 2013, Pages 136-141

  Raederstorff, Daniel ^a   Kunz, Iris ^a   Schwager, Joseph ^a  

^a DSM NUTRITIONAL PRODUCTS LTD   (Switzerland)

Author keywords

Aging; Cardiovascular; Inflammation; Metabolic disorders; Resveratrol

Indexed keywords

GLUCOSE; RESVERATROL;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CALORIC RESTRICTION; CARDIOVASCULAR EFFECT; CORONARY ARTERY DISEASE; DRUG MEGADOSE; FOOD COMPOSITION; GLUCOSE BLOOD LEVEL; GRAPE; HEART PROTECTION; HUMAN; INSULIN SENSITIVITY; LIFESTYLE; LIVER INJURY; LOW DRUG DOSE; MEDICINAL PLANT; METABOLISM; NONHUMAN; NUTRITION; OBESITY; PLEIOTROPY; SINGLE DRUG DOSE; SUPPLEMENTATION;

EID: 84880385970     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12147     Document Type: Article

References (45)

1. Takaoka, M. 1940. Phenolic substance of white hellebore (Veratrum grandiflorum Loes fil.). III. Constitution of resveratrol. Nippon Kagaku Kaishi 61: 30-34.
2. Renaud, S. & M. de Lorgeril. 1992. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339: 1523-1526.
3. Frankel, E.N., A.L. Waterhouse & J.E. Kinsella. 1993. Inhibition of human LDL oxidation by resveratrol. Lancet 341: 1103-1104.
4. Lippi, G., M. Franchini, E.J. Favaloro, et al. 2010. Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox". Semin. Thromb. Hemost. 36: 59-70.
5. Bertelli, A.A.E., L. Giovannini, D. Giannessi, et al. 1995. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tissue Reac. 17: 1-3.
6. Howitz, K.T., K.J. Bitterman, H.Y. Cohen, et al. 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
7. Baur, J.A. & D.A. Sinclair. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5: 493-506.
8. Chachay, V.S., C.M. Kirkpatrick, I.J. Hickman, et al. 2011. Resveratrol-pills to replace a healthy diet? Br. J. Clin. Pharmacol. 72: 27-38.
9. Timmers, S., J. Auwerx & P. Schrauwen. 2012. The journey of resveratrol from yeast to human. Aging 4: 146-158.
10. Jang, M., L. Cai, G.O. Udeani, et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.
11. Scott, E., W.P. Steward, A.J. Gescher, et al. 2012. Resveratrol in human cancer chemoprevention-choosing the 'right' dose. Mol. Nutr. Food Res. 56: 7-13.
12. Whitlock, N.C. & S.J. Baek. 2012. The anticancer effects of resveratrol: modulation of transcription factors. Nutr. Cancer 64: 493-502.
13. Center for Drug Evaluation and Research. 2005. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Food and Drug Administration, Rockville, Maryland, USA.
14. Reagan-Shaw, S., M. Nihal & N. Ahmad. 2008. Dose translation from animal to human studies revisited. FASEB J. 22: 659-661.
15. Baur, J.A. 2010. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech. Ageing Dev. 131: 261-269.
16. Wong, R.H., P.R. Howe, J.D. Buckley, et al. 2011. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis. 21: 851-856.
17. Brasnyo, P., G.A. Molnar, M. Mohas, et al. 2011. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106: 383-389.
18. Timmers, S., E. Konings, L. Bilet, et al. 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14: 612-622.
19. Magyar, K., R. Halmosi, A. Palfi, et al. 2012. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 50: 179-187.
20. Yoshino, J., C. Conte, L. Fontana, et al. 2012. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 16: 658-664.
21. Poulsen, M.M., P.F. Vestergaard, B.F. Clasen, et al. 2013. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62: 1186-1195.
22. Crandall, J.P., V. Oram, G. Trandafirescu, et al. 2012. Pilot study of resveratrol in older adults with impaired glucose tolerance. J. Gerontol. A Biol. Sci. Med. Sci. 67: 1307-1312.
23. Baur, J.A., K.J. Pearson, N.L. Price, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342.
24. Martin, G.M. 2011. The biology of aging: 1985-2010 and beyond. FASEB J. 25: 3756-3762.
25. Fontana, L., L. Partridge & V.D. Longo. 2010. Extending healthy life span-from yeast to humans. Science 328: 321-326.
26. Liu, M., S.A. Wilk, A. Wang, et al. 2010. Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J. Biol. Chem. 285: 36387-36394.
27. Park, S.J., F. Ahmad, A. Philp, et al. 2012. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421-433.
28. Barger, J.L., T. Kayo, J.M. Vann, et al. 2008. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 3: e2264.
29. Bhatt, J.K., S. Thomas & M.J. Nanjan. 2012. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 32: 537-541.
30. Schmitt, C.A., E.H. Heiss & V.M. Dirsch. 2010. Effect of resveratrol on endothelial cell function: molecular mechanisms. Biofactors 36: 342-349.
31. Ferrero, M.E., A. E. Bertelli, A. Fulgenzi, et al. 1998. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am. J. Clin. Nutr. 68: 1208-1214.
32. Csiszar, A., K. Smith, N. Labinskyy, et al. 2006. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kB inhibition. Am. J. Physiol. Heart Circ. Physiol. 291: H1694-H1699.
33. Ungvari, Z., Z. Orosz, N. Labinskyy, et al. 2007. Increased mitochondrial H2O2 production promotes endothelial NF-kappaB activation in aged rat arteries. Am. J. Physiol. Heart Circ. Physiol. 293: H37-H47.
34. Agarwal, B., M.J. Campen, M.M. Channell, et al. 2013. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int. J. Cardiol. In press.
35. Ungvari, Z., Z. Bagi, A. Feher, et al. 2010. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart. Circ. Physiol. 299: H18-H24.
36. Ghanim, H., C.L. Sia, K. Korzeniewski, et al. 2011. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J. Clin. Endocrinol. Metab. 96: 1409-1414.
37. Wallerath, T., G. Deckert, T. Ternes, et al. 2002. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106: 1652-1658.
38. Takahashi, S. & Y. Nakashima. 2012. Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells. Br. J. Nutr. 107: 774-780.
39. Bhatt, S.R., M.F. Lokhandwala & A.A. Banday. 2011. Resveratrol prevents endothelial nitric oxide synthase uncoupling and attenuates development of hypertension in spontaneously hypertensive rats. Eur. J. Pharmacol. 667: 258-264.
40. Walle, T., F. Hsieh, M.H. DeLegge, et al. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32: 1377-1382.
41. Vitrac, X., A. Desmouliere, B. Brouillaud, et al. 2003. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 72: 2219-2233.
42. Lin, S.P., P.M. Chu, S.Y. Tsai, et al. 2012. Pharmacokinetics and tissue distribution of resveratrol, emodin and their metabolites after intake of Polygonum cuspidatum in rats. J. Ethnopharmacol. 144: 671-676.
43. Hoshino, J., E.J. Park, T.P. Kondratyuk, et al. 2010. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 53: 5033-5043.
44. Wong, R.H., N.M. Berry, A.M. Coates, et al. 2012. Sustained improvement of vasodilator function by resveratrol in obese adults. J. Hypertens. 30: e70.
45. Shechter, M., A. Issachar, I. Marai, et al. 2009. Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Int. J. Cardiol. 134: 52-58.